Supplementary Table S7.

Details of Individuals Analyzed for IFN Score Validation

Group	Individuals with Active Disease	Sex	Average Age, y	Treatment
CAPS	4/9	3M, 6F	44.6	cankinumab (n = 7), anakinra (n = 2)
GPP	11/17	2M, 15F	56.5	adalimumab (n = 3), certolizumab (n = 1), infliximab (n = 2), ustekinumab (n = 1), acitretin (n = 1), ciclosporin (n = 2), MTX (n = 1), prednisolone (n = 1), topical treatment (n = 4), no treatment (n = 1)
PV	17/17	13M, 4F	42.5	apremilast (n = 1), etanercept (n = 1), infliximab (n = 1), ixekizumab (n = 1), secukinumab (n = 1), ustekinumab (n = 4), MTX (n = 1), topical treatment (n = 6), PUVA (n = 1)
Control	NA	3M, 23F	46.4	NA

Abbreviations: CAPS, cryopyrin associated periodic syndrome; F, female; GPP, generalized pustular psoriasis; M, male; NA, not applicable; PV, psoriasis vulgaris; MTX, Methotrexate

The percentage of patients receiving systemic treatment was comparable in the PV-only and PV with psoriatic arthritis groups.